# EDGAR Filing Document

**Accession Number:** 0000102816
**File Stem:** 0001752724-23-014876
**Filing Date:** 2023-1
**Character Count:** 37062
**Document Hash:** ebc50d8c6b4af79c4fec31132182bf17
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001752724-23-014876.hdr.sgml**: 20230126

**ACCESSION NUMBER**: 0001752724-23-014876

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221130

**FILED AS OF DATE**: 20230126

**DATE AS OF CHANGE**: 20230126

**PERIOD START**: 20230831

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EATON VANCE GROWTH TRUST
- **CENTRAL INDEX KEY:** 0000102816
- **IRS NUMBER:** 042325690

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-01241
- **FILM NUMBER:** 23557030

**BUSINESS ADDRESS:**
- **STREET 1:** TWO INTERNATIONAL PLACE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 617-482-8260

**MAIL ADDRESS:**
- **STREET 1:** TWO INTERNATIONAL PLACE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EATON VANCE GROWTH FUND INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VANCE SANDERS COMMON STOCK FUND INC
- **DATE OF NAME CHANGE:** 19820915

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BOSTON STOCK FUND INC
- **DATE OF NAME CHANGE:** 19730619

## Series and Classes Contracts Data

### Eaton Vance Worldwide Health Sciences Fund (Series ID: S000005202)

| Class ID   | Class Name                                         | Ticker Symbol   |
|:---|:---|:---|
| C000014191 | Eaton Vance Worldwide Health Sciences Fund Class A | ETHSX           |
| C000014193 | Eaton Vance Worldwide Health Sciences Fund Class C | ECHSX           |
| C000014194 | Eaton Vance Worldwide Health Sciences Fund Class R | ERHSX           |
| C000081646 | Eaton Vance Worldwide Health Sciences Fund Class I | EIHSX           |

## Nport-Ex

Eaton Vance<br>

Worldwide Health Sciences Fund

November 30, 2022

Portfolio of Investments (Unaudited)

------

Common Stocks — 97.9%

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Biotechnology — 12.8% | Biotechnology — 12.8% | Biotechnology — 12.8% |
| AbbVie, Inc. | 354650 | &nbsp;&nbsp;$57162487 |
| Abcam PLC<sup>(1)</sup> | 371519 | &nbsp;&nbsp;&nbsp;&nbsp; 5823649 |
| argenx SE ADR<sup>(1)</sup> | 22042 | &nbsp;&nbsp;&nbsp;&nbsp; 8772054 |
| Blueprint Medicines Corp.<sup>(1)</sup> | 51234 | &nbsp;&nbsp;&nbsp;&nbsp; 2448473 |
| CSL, Ltd. | 101354 | &nbsp;&nbsp;&nbsp;&nbsp; 20824045 |
| Gilead Sciences, Inc. | 214388 | &nbsp;&nbsp;&nbsp;&nbsp; 18829698 |
| Neurocrine Biosciences, Inc.<sup>(1)</sup> | 170963 | &nbsp;&nbsp;&nbsp;&nbsp; 21722559 |
| Travere Therapeutics, Inc.<sup>(1)</sup> | 121514 | &nbsp;&nbsp;&nbsp;&nbsp; 2446077 |
|  |  | &nbsp;&nbsp;**$138029042** |
| Containers & Packaging — 0.4% | Containers & Packaging — 0.4% | Containers & Packaging — 0.4% |
| AptarGroup, Inc. | 44675 | &nbsp;&nbsp;$4741804 |
|  |  | &nbsp;&nbsp;**$4741804** |
| Health Care Equipment — 13.9% | Health Care Equipment — 13.9% | Health Care Equipment — 13.9% |
| Boston Scientific Corp.<sup>(1)</sup> | 550105 | &nbsp;&nbsp;$24903253 |
| Envista Holdings Corp.<sup>(1)</sup> | 206075 | &nbsp;&nbsp;&nbsp;&nbsp; 7031279 |
| Fisher & Paykel Healthcare Corp., Ltd. | 306830 | &nbsp;&nbsp;&nbsp;&nbsp; 4595281 |
| Inari Medical, Inc.<sup>(1)</sup> | 151170 | &nbsp;&nbsp;&nbsp;&nbsp; 11123089 |
| Intuitive Surgical, Inc.<sup>(1)</sup> | 121108 | &nbsp;&nbsp;&nbsp;&nbsp; 32746392 |
| Straumann Holding AG | 84956 | &nbsp;&nbsp;&nbsp;&nbsp; 9915334 |
| Stryker Corp. | 111116 | &nbsp;&nbsp;&nbsp;&nbsp; 25988921 |
| Teleflex, Inc. | 57793 | &nbsp;&nbsp;&nbsp;&nbsp; 13530497 |
| Zimmer Biomet Holdings, Inc. | 165049 | &nbsp;&nbsp;&nbsp;&nbsp; 19822385 |
|  |  | &nbsp;&nbsp;**$149656431** |
| Health Care Services — 1.5% | Health Care Services — 1.5% | Health Care Services — 1.5% |
| Agiliti, Inc.<sup>(1)</sup> | 702673 | &nbsp;&nbsp;$11601131 |
| R1 RCM, Inc.<sup>(1)</sup> | 444015 | &nbsp;&nbsp;&nbsp;&nbsp; 4018336 |
|  |  | &nbsp;&nbsp;**$15619467** |
| Health Care Supplies — 3.7% | Health Care Supplies — 3.7% | Health Care Supplies — 3.7% |
| Alcon, Inc. | 223253 | &nbsp;&nbsp;$15395445 |
| Asahi Intecc Co., Ltd. | 255800 | &nbsp;&nbsp;&nbsp;&nbsp; 4579034 |
| Cooper Cos., Inc. (The) | 41324 | &nbsp;&nbsp;&nbsp;&nbsp; 13072847 |
| Neogen Corp.<sup>(1)</sup> | 420833 | &nbsp;&nbsp;&nbsp;&nbsp; 6968995 |
|  |  | &nbsp;&nbsp;**$40016321** |
| Health Care Technology — 1.3% | Health Care Technology — 1.3% | Health Care Technology — 1.3% |
| JMDC, Inc. | 173100 | &nbsp;&nbsp;$6641136 |
| M3, Inc. | 226300 | &nbsp;&nbsp;&nbsp;&nbsp; 7097395 |
|  |  | &nbsp;&nbsp;**$13738531** |

---

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Life Sciences Tools & Services — 12.0% | Life Sciences Tools & Services — 12.0% | Life Sciences Tools & Services — 12.0% |
| Danaher Corp. | 164944 | &nbsp;&nbsp;$45097339 |
| Lonza Group AG | 25000 | &nbsp;&nbsp;&nbsp;&nbsp; 13152306 |
| Thermo Fisher Scientific, Inc. | 89567 | &nbsp;&nbsp;&nbsp;&nbsp; 50177225 |
| Waters Corp.<sup>(1)</sup> | 58647 | &nbsp;&nbsp;&nbsp;&nbsp; 20327050 |
|  |  | &nbsp;&nbsp;**$128753920** |
| Managed Health Care — 11.6% | Managed Health Care — 11.6% | Managed Health Care — 11.6% |
| Centene Corp.<sup>(1)</sup> | 240819 | &nbsp;&nbsp;$20963294 |
| Humana, Inc. | 27524 | &nbsp;&nbsp;&nbsp;&nbsp; 15135447 |
| UnitedHealth Group, Inc. | 162634 | &nbsp;&nbsp;&nbsp;&nbsp; 89084400 |
|  |  | &nbsp;&nbsp;**$125183141** |
| Pharmaceuticals — 40.7% | Pharmaceuticals — 40.7% | Pharmaceuticals — 40.7% |
| AstraZeneca PLC | 327456 | &nbsp;&nbsp;$44318112 |
| Bristol-Myers Squibb Co. | 550361 | &nbsp;&nbsp;&nbsp;&nbsp; 44182981 |
| Dechra Pharmaceuticals PLC | 138439 | &nbsp;&nbsp;&nbsp;&nbsp; 4572245 |
| Eli Lilly & Co. | 146506 | &nbsp;&nbsp;&nbsp;&nbsp; 54365446 |
| Johnson & Johnson | 441261 | &nbsp;&nbsp;&nbsp;&nbsp; 78544458 |
| Merck & Co., Inc. | 163675 | &nbsp;&nbsp;&nbsp;&nbsp; 18023891 |
| Novo Nordisk A/S, Class B | 399038 | &nbsp;&nbsp;&nbsp;&nbsp; 50054546 |
| Pfizer, Inc. | 359209 | &nbsp;&nbsp;&nbsp;&nbsp; 18007147 |
| Roche Holding AG PC | 159632 | &nbsp;&nbsp;&nbsp;&nbsp; 52139620 |
| Royalty Pharma PLC, Class A | 320270 | &nbsp;&nbsp;&nbsp;&nbsp; 14082272 |
| Sanofi | 368356 | &nbsp;&nbsp;&nbsp;&nbsp; 33273332 |
| Zoetis, Inc. | 167945 | &nbsp;&nbsp;&nbsp;&nbsp; 25887042 |
|  |  | &nbsp;&nbsp;**$437451092** |
| Total Common Stocks<br> (identified cost $672,623,914) |  | &nbsp;&nbsp;**$1053189749** |

---

Convertible Preferred Stocks — 0.1%

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Biotechnology — 0.1% | Biotechnology — 0.1% | Biotechnology — 0.1% |
| Caris Life Sciences, Inc., Series D<sup>(1)(2)(3)</sup> | 370370 | &nbsp;&nbsp;$774073 |
| Total Convertible Preferred Stocks<br> (identified cost $3,000,000) |  | &nbsp;&nbsp;**$774073** |

---

------

Eaton Vance<br>

Worldwide Health Sciences Fund

November 30, 2022

Portfolio of Investments (Unaudited) — continued

------

Exchange-Traded Funds — 1.5%

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Equity Funds — 1.5% | Equity Funds — 1.5% | Equity Funds — 1.5% |
| SPDR S&P Biotech ETF | 194177 | &nbsp;&nbsp;$16237081 |
| Total Exchange-Traded Funds<br> (identified cost $13,774,141) |  | &nbsp;&nbsp;**$16237081** |

---

Short-Term Investments — 0.0%<sup>(4)</sup>

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Morgan Stanley Institutional Liquidity Funds - Government Portfolio, Institutional Class, 3.62%<sup>(5)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;9121 | &nbsp;&nbsp;$9121 |
| Total Short-Term Investments<br> (identified cost $9,121) |  | &nbsp;&nbsp;**$9121** |
| Total Investments — 99.5%<br> (identified cost $689,407,176) |  | &nbsp;&nbsp;**$1070210024** |
| Other Assets, Less Liabilities — 0.5% |  | &nbsp;&nbsp;**$5006227** |
| Net Assets — 100.0% |  | &nbsp;&nbsp;**$1075216251** |

---

---

| | |
|:---|:---|
| The percentage shown for each investment category in the Portfolio of Investments is based on net assets. | The percentage shown for each investment category in the Portfolio of Investments is based on net assets. |
| <sup>(1)</sup> | Non-income producing security. |
| <sup>(2)</sup> | For fair value measurement disclosure purposes, security is categorized as Level 3. |
| <sup>(3)</sup> | Restricted security. |

---

<sup>(4)</sup> Amount is less than 0.05%.

<sup>(5)</sup> May be deemed to be an affiliated investment company. The rate shown is the annualized seven-day yield as of November 30, 2022.

---

| | | |
|:---|:---|:---|
| Country Concentration of Portfolio | Country Concentration of Portfolio | Country Concentration of Portfolio |
| **Country** | &nbsp;&nbsp;&nbsp;**Percentage<br> of Net Assets** | &nbsp;&nbsp;&nbsp;**Value** |
| United States | &nbsp;&nbsp;&nbsp;70.6% | &nbsp;&nbsp;&nbsp;&nbsp;$758737137 |
| Switzerland | &nbsp;&nbsp;&nbsp;&nbsp;8.4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;90602705 |
| United Kingdom | &nbsp;&nbsp;&nbsp;&nbsp;6.4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;68796278 |
| Denmark | &nbsp;&nbsp;&nbsp;&nbsp;4.7 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;50054546 |
| France | &nbsp;&nbsp;&nbsp;&nbsp;3.1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33273332 |
| Australia | &nbsp;&nbsp;&nbsp;&nbsp;1.9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20824045 |
| Japan | &nbsp;&nbsp;&nbsp;&nbsp;1.7 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18317565 |
| Netherlands | &nbsp;&nbsp;&nbsp;&nbsp;0.8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8772054 |
| New Zealand | &nbsp;&nbsp;&nbsp;&nbsp;0.4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4595281 |
| Exchange-Traded Funds | &nbsp;&nbsp;&nbsp;&nbsp;1.5 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16237081 |
| **Total Investments** | &nbsp;&nbsp;&nbsp;**99.5%** | &nbsp;&nbsp;&nbsp;**$1070210024** |

---

---

| | |
|:---|:---|
| **Abbreviations:** | **Abbreviations:** |
| ADR | – American Depositary Receipt |
| PC | – Participation Certificate |

---

The Fund did not have any open derivative instruments at November 30, 2022.

Restricted Securities

At November 30, 2022, the Fund owned the following security (representing 0.1% of net assets) which was restricted as to public resale and not registered under the Securities Act of 1933 (excluding Rule 144A securities). The Fund has limited registration rights with respect to this security. The value of restricted securities is determined based on valuations provided by brokers when available, or if not available, they are valued by the investment adviser as the Trustees' valuation designee.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Description** | &nbsp;&nbsp;&nbsp;&nbsp;**Date(s) of<br> Acquisition** | &nbsp;&nbsp;&nbsp;&nbsp;**Shares** | &nbsp;&nbsp;&nbsp;&nbsp;**Cost** | &nbsp;&nbsp;&nbsp;&nbsp;**Value** |
| **Convertible Preferred Stocks** |  |  |  |  |
| Caris Life Sciences, Inc., Series D | &nbsp;&nbsp;&nbsp;&nbsp;5/12/21, 9/23/21 | &nbsp;&nbsp;&nbsp;&nbsp;370370 | &nbsp;&nbsp;&nbsp;&nbsp;$3000000 | &nbsp;&nbsp;&nbsp;&nbsp;$774073 |
| **Total Restricted Securities** |  |  | &nbsp;&nbsp;&nbsp;&nbsp;**$3000000** | &nbsp;&nbsp;&nbsp;&nbsp;**$774073** |

---

------

Eaton Vance<br>

Worldwide Health Sciences Fund

November 30, 2022

Portfolio of Investments (Unaudited) — continued

------

Affiliated Investments

At November 30, 2022, the value of the Fund's investment in Morgan Stanley Institutional Liquidity Funds - Government Portfolio (Liquidity Fund) was $9,121, which represents less than 0.05% of the Fund's net assets. Transactions in funds that may be deemed to be affiliated by the Fund for the fiscal year to date ended November 30, 2022 were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Value,<br> beginning<br> of period** | **Purchases** | **Sales<br> proceeds** | **Net<br> realized<br> gain (loss)** | **Change in<br> unrealized<br> appreciation<br> (depreciation)** | **Value, end<br> of period** | **Dividend<br> income** | **Shares,<br> end of period** |
| **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** |
| Liquidity Fund | $1945086 | $16333962 | $(18269927) | $— | $— | $9121 | $5673 | 9121 |

---

Fair Value Measurements

Under generally accepted accounting principles for fair value measurements, a three-tier hierarchy to prioritize the assumptions, referred to as inputs, is used in valuation techniques to measure fair value. The three-tier hierarchy of inputs is summarized in the three broad levels listed below.

• Level 1 – quoted prices in active markets for identical investments

• Level 2 – other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)

• Level 3 – significant unobservable inputs (including a fund's own assumptions in determining the fair value of investments)

In cases where the inputs used to measure fair value fall in different levels of the fair value hierarchy, the level disclosed is determined based on the lowest level input that is significant to the fair value measurement in its entirety. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

At November 30, 2022, the hierarchy of inputs used in valuing the Fund's investments, which are carried at value, were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Asset Description** | &nbsp;&nbsp;**Level 1** | &nbsp;&nbsp;**Level 2** | &nbsp;&nbsp;**Level 3\*** | &nbsp;&nbsp;**Total** |
| Common Stocks: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Biotechnology | &nbsp;&nbsp;$111381348 | &nbsp;&nbsp;$26647694 | &nbsp;&nbsp;$— | &nbsp;&nbsp;$138029042 |
| &nbsp;&nbsp;&nbsp;Containers & Packaging | &nbsp;&nbsp;&nbsp;&nbsp; 4741804 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 4741804 |
| &nbsp;&nbsp;&nbsp;Health Care Equipment | &nbsp;&nbsp;&nbsp;&nbsp;135145816 | &nbsp;&nbsp;&nbsp;&nbsp; 14510615 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 149656431 |
| &nbsp;&nbsp;&nbsp;Health Care Services | &nbsp;&nbsp;&nbsp;&nbsp; 15619467 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 15619467 |
| &nbsp;&nbsp;&nbsp;Health Care Supplies | &nbsp;&nbsp;&nbsp;&nbsp; 20041842 | &nbsp;&nbsp;&nbsp;&nbsp; 19974479 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 40016321 |
| &nbsp;&nbsp;&nbsp;Health Care Technology | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 13738531 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 13738531 |
| &nbsp;&nbsp;&nbsp;Life Sciences Tools & Services | &nbsp;&nbsp;&nbsp;&nbsp;115601614 | &nbsp;&nbsp;&nbsp;&nbsp; 13152306 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 128753920 |
| &nbsp;&nbsp;&nbsp;Managed Health Care | &nbsp;&nbsp;&nbsp;&nbsp;125183141 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 125183141 |
| &nbsp;&nbsp;&nbsp;Pharmaceuticals | &nbsp;&nbsp;&nbsp;&nbsp;253093237 | &nbsp;&nbsp;&nbsp;&nbsp;184357855 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 437451092 |
| **Total Common Stocks** | &nbsp;&nbsp;**$780808269** | &nbsp;&nbsp;**$272,381,480\*\*** | &nbsp;&nbsp;**$—** | &nbsp;&nbsp;**$1053189749** |
| Convertible Preferred Stocks | &nbsp;&nbsp;$— | &nbsp;&nbsp;$— | &nbsp;&nbsp;$774073 | &nbsp;&nbsp;$774073 |
| Exchange-Traded Funds | &nbsp;&nbsp;&nbsp;&nbsp; 16237081 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 16237081 |
| Short-Term Investments | &nbsp;&nbsp;&nbsp;&nbsp; 9121 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 9121 |
| **Total Investments** | &nbsp;&nbsp;**$797054471** | &nbsp;&nbsp;**$272381480** | &nbsp;&nbsp;**$774073** | &nbsp;&nbsp;**$1070210024** |

---

\* None of the unobservable inputs for Level 3 assets, individually or collectively, had a material impact on the Fund.

\*\* Includes foreign equity securities whose values were adjusted to reflect market trading of comparable securities or other correlated instruments that occurred after the close of trading in their applicable foreign markets.

Level 3 investments at the beginning and/or end of the period in relation to net assets were not significant and accordingly, a reconciliation of Level 3 assets for the fiscal year to date ended November 30, 2022 is not presented.

------

Eaton Vance<br>

Worldwide Health Sciences Fund

November 30, 2022

Portfolio of Investments (Unaudited) — continued

------

For information on the Fund's policy regarding the valuation of investments and other significant accounting policies, please refer to the Fund's most recent financial statements included in its semiannual or annual report to shareholders.

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** EATON VANCE GROWTH TRUST

- **b. Investment Company Act file number:** 811-01241

- **c. CIK number of Registrant:** 0000102816

- **d. LEI of Registrant:** 549300IUJG72RXOVY252

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** TWO INTERNATIONAL PLACE

  - **City:** BOSTON

  - **State:** MA

  - **Foreign country:** US

  - **Zip / Postal Code:** 02110

  - **Telephone number:** 617-482-8260

**Item A.2. Information about the Series.**

- **a. Name of Series:** Eaton Vance Worldwide Health Sciences Fund

- **b. EDGAR series identifier (if any):** S000005202

- **c. LEI of Series:** 549300CI26YJYCASE766

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2023-08-31

- **b. Date as of which information is reported:** 2022-11-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $1077678706.50

**Total Liabilities:** $1821341.82

**Net Assets:** $1075857364.68

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000081646 | -4.35%               | 7.31%                | 5.37%                |
| Class ID C000014193 | -4.51%               | 7.30%                | 5.26%                |
| Class ID C000014191 | -4.42%               | 7.39%                | 5.32%                |
| Class ID C000014194 | -4.44%               | 7.28%                | 5.27%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $4026510.39              | $-48331443.71                              |
| Month 2  | $7770565.04              | $62975695.43                               |
| Month 3  | $5167017.40              | $48849052.27                               |

### Schedule of Portfolio Investments

| Name                                | Title                                                               | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Neogen Corp                         | Neogen Corp                                                         | CUSIP: 640491106<br>LEI: 549300HJT9FC36N4UW43 | Long             | EC               | CORP              | US        |    420833 | NS      | $6968994.48   | 0.65%             |  |  |  | No            |                  1 | On Loan: No      |
| R1 RCM Inc                          | R1 RCM Inc                                                          | CUSIP: 77634L105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    444015 | NS      | $4018335.75   | 0.37%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                   | Johnson & Johnson                                                   | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |    441261 | NS      | $78544458.00  | 7.30%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc              | UnitedHealth Group Inc                                              | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |    162634 | NS      | $89084399.84  | 8.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Straumann Holding AG                | Straumann Holding AG                                                | CUSIP: 000000000<br>LEI: 50670046ML5FVIM60Z37 | Long             | EC               | CORP              | CH        |     84956 | NS      | $9915333.95   | 0.92%             |  |  |  | No            |                  2 | On Loan: No      |
| AbbVie Inc                          | AbbVie Inc                                                          | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |    354650 | NS      | $57162487.00  | 5.31%             |  |  |  | No            |                  1 | On Loan: No      |
| Agiliti Inc                         | Agiliti Inc                                                         | CUSIP: 00848J104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    702673 | NS      | $11601131.23  | 1.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc        | Thermo Fisher Scientific Inc                                        | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |     89567 | NS      | $50177224.74  | 4.66%             |  |  |  | No            |                  1 | On Loan: No      |
| Novo Nordisk A/S                    | Novo Nordisk A/S                                                    | CUSIP: 000000000<br>LEI: 549300DAQ1CVT6CXN342 | Long             | EC               | CORP              | DK        |    399038 | NS      | $50054545.97  | 4.65%             |  |  |  | No            |                  2 | On Loan: No      |
| Travere Therapeutics Inc            | Travere Therapeutics Inc                                            | CUSIP: 89422G107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    121514 | NS      | $2446076.82   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Abcam PLC                           | Abcam PLC                                                           | CUSIP: 000000000<br>LEI: 213800B9N83DSNT33F79 | Long             | EC               | CORP              | GB        |    371519 | NS      | $5823649.20   | 0.54%             |  |  |  | No            |                  2 | On Loan: No      |
| Inari Medical Inc                   | Inari Medical Inc                                                   | CUSIP: 45332Y109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    151170 | NS      | $11123088.60  | 1.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Centene Corp                        | Centene Corp                                                        | CUSIP: 15135B101<br>LEI: 549300Z7JJ4TQSQGT333 | Long             | EC               | CORP              | US        |    240819 | NS      | $20963293.95  | 1.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG                    | Roche Holding AG                                                    | CUSIP: 000000000<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |    159632 | NS      | $52139620.10  | 4.85%             |  |  |  | No            |                  2 | On Loan: No      |
| Zoetis Inc                          | Zoetis Inc                                                          | CUSIP: 98978V103<br>LEI: 549300HD9Q1LOC9KLJ48 | Long             | EC               | CORP              | US        |    167945 | NS      | $25887042.30  | 2.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Boston Scientific Corp              | Boston Scientific Corp                                              | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |    550105 | NS      | $24903253.35  | 2.31%             |  |  |  | No            |                  1 | On Loan: No      |
| Zimmer Biomet Holdings Inc          | Zimmer Biomet Holdings Inc                                          | CUSIP: 98956P102<br>LEI: 2P2YLDVPES3BXQ1FRB91 | Long             | EC               | CORP              | US        |    165049 | NS      | $19822384.90  | 1.84%             |  |  |  | No            |                  1 | On Loan: No      |
| Dechra Pharmaceuticals PLC          | Dechra Pharmaceuticals PLC                                          | CUSIP: 000000000<br>LEI: 213800J4UVB5OWG8VX82 | Long             | EC               | CORP              | GB        |    138439 | NS      | $4572244.88   | 0.42%             |  |  |  | No            |                  2 | On Loan: No      |
| Stryker Corp                        | Stryker Corp                                                        | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |    111116 | NS      | $25988921.24  | 2.42%             |  |  |  | No            |                  1 | On Loan: No      |
| M3 Inc                              | M3 Inc                                                              | CUSIP: 000000000<br>LEI: 3538001UOKRWIODYM055 | Long             | EC               | CORP              | JP        |    226300 | NS      | $7097395.14   | 0.66%             |  |  |  | No            |                  2 | On Loan: No      |
| JMDC Inc                            | JMDC Inc                                                            | CUSIP: 000000000<br>LEI: 3538002M2SQV6WJ6MQ67 | Long             | EC               | CORP              | JP        |    173100 | NS      | $6641135.37   | 0.62%             |  |  |  | No            |                  2 | On Loan: No      |
| AstraZeneca PLC                     | AstraZeneca PLC                                                     | CUSIP: 000000000<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |    327456 | NS      | $44318111.71  | 4.12%             |  |  |  | No            |                  2 | On Loan: No      |
| Intuitive Surgical Inc              | Intuitive Surgical Inc                                              | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |    121108 | NS      | $32746392.12  | 3.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Alcon Inc                           | Alcon Inc                                                           | CUSIP: 000000000<br>LEI: 549300LDT5AP8S0NBM78 | Long             | EC               | CORP              | CH        |    223253 | NS      | $15395445.01  | 1.43%             |  |  |  | No            |                  2 | On Loan: No      |
| Fisher & Paykel Healthcare Corp Ltd | Fisher & Paykel Healthcare Corp Ltd                                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | NZ        |    306830 | NS      | $4595280.81   | 0.43%             |  |  |  | No            |                  2 | On Loan: No      |
| AptarGroup Inc                      | AptarGroup Inc                                                      | CUSIP: 038336103<br>LEI: VNPEQDQFAA7IY1T2PX43 | Long             | EC               | CORP              | US        |     44675 | NS      | $4741804.50   | 0.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Blueprint Medicines Corp            | Blueprint Medicines Corp                                            | CUSIP: 09627Y109<br>LEI: 5299004CC60O9T5HVM83 | Long             | EC               | CORP              | US        |     51234 | NS      | $2448472.86   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Lonza Group AG                      | Lonza Group AG                                                      | CUSIP: 000000000<br>LEI: 549300EFW4H2TCZ71055 | Long             | EC               | CORP              | CH        |     25000 | NS      | $13152305.57  | 1.22%             |  |  |  | No            |                  2 | On Loan: No      |
| Asahi Intecc Co Ltd                 | Asahi Intecc Co Ltd                                                 | CUSIP: 000000000<br>LEI: 353800J3AV2SCNIO8L39 | Long             | EC               | CORP              | JP        |    255800 | NS      | $4579033.67   | 0.43%             |  |  |  | No            |                  2 | On Loan: No      |
| Envista Holdings Corp               | Envista Holdings Corp                                               | CUSIP: 29415F104<br>LEI: 549300BX623VURJZ5269 | Long             | EC               | CORP              | US        |    206075 | NS      | $7031279.00   | 0.65%             |  |  |  | No            |                  1 | On Loan: No      |
| CSL Ltd                             | CSL Ltd                                                             | CUSIP: 000000000<br>LEI: 529900ECSECK5ZDQTE14 | Long             | EC               | CORP              | AU        |    101354 | NS      | $20824044.75  | 1.94%             |  |  |  | No            |                  2 | On Loan: No      |
| Pfizer Inc                          | Pfizer Inc                                                          | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |    359209 | NS      | $18007147.17  | 1.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                           | Argenx SE                                                           | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     22042 | NS      | $8772054.74   | 0.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Morgan Stanley & Co. LLC            | Morgan Stanley Institutional Liquidity Funds - Government Portfolio | CUSIP: 61747C707<br>LEI: 549300BI6Y5SI6BYPB26 | Long             | STIV             | RF                | US        |      9121 | NS      | $9120.52      | 0.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Sanofi                              | Sanofi                                                              | CUSIP: 000000000<br>LEI: 549300E9PC51EN656011 | Long             | EC               | CORP              | FR        |    368356 | NS      | $33273331.56  | 3.09%             |  |  |  | No            |                  2 | On Loan: No      |
| Neurocrine Biosciences Inc          | Neurocrine Biosciences Inc                                          | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |    170963 | NS      | $21722558.78  | 2.02%             |  |  |  | No            |                  1 | On Loan: No      |
| SPDR S&P Biotech ETF                | SPDR S&P Biotech ETF                                                | CUSIP: 78464A870<br>LEI: 549300Y3ODFMPD5XXL58 | Long             | EC               | RF                | US        |    194177 | NS      | $16237080.74  | 1.51%             |  |  |  | No            |                  1 | On Loan: No      |
| Humana Inc                          | Humana Inc                                                          | CUSIP: 444859102<br>LEI: 529900YLDW34GJAO4J06 | Long             | EC               | CORP              | US        |     27524 | NS      | $15135447.60  | 1.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp                        | Danaher Corp                                                        | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |    164944 | NS      | $45097339.04  | 4.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Teleflex Inc                        | Teleflex Inc                                                        | CUSIP: 879369106<br>LEI: UUL85LWXB4NGSWWXIQ25 | Long             | EC               | CORP              | US        |     57793 | NS      | $13530497.16  | 1.26%             |  |  |  | No            |                  1 | On Loan: No      |
| CARIS LIFE SCIENCES, INC            | CARIS LIFE SCIENCES, INC                                            | CUSIP: 000000000<br>LEI: N/A                  | Long             | EP               | CORP              | US        |    370370 | NS      | $774073.30    | 0.07%             |  |  |  | No            |                  3 | On Loan: No      |
| Merck & Co Inc                      | Merck & Co Inc                                                      | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |    201902 | NS      | $22233448.24  | 2.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Cooper Cos Inc/The                  | Cooper Cos Inc/The                                                  | CUSIP: 216648402<br>LEI: QJKMVPIGLH7530PCUE20 | Long             | EC               | CORP              | US        |     41324 | NS      | $13072847.40  | 1.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Waters Corp                         | Waters Corp                                                         | CUSIP: 941848103<br>LEI: 5T547R1474YC9HOD8Q74 | Long             | EC               | CORP              | US        |     58647 | NS      | $20327050.20  | 1.89%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                      | Eli Lilly & Co                                                      | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |    146506 | NS      | $54365446.48  | 5.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Royalty Pharma PLC                  | Royalty Pharma PLC                                                  | CUSIP: 000000000<br>LEI: 549300FGFN7VOK8BZR03 | Long             | EC               | CORP              | GB        |    320270 | NS      | $14082271.90  | 1.31%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co             | Bristol-Myers Squibb Co                                             | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |    550361 | NS      | $44182981.08  | 4.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc                 | Gilead Sciences Inc                                                 | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    214388 | NS      | $18829698.04  | 1.75%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2022-12-22

**Name of Applicant:** EATON VANCE GROWTH TRUST

**Signature:** James Kirchner

**Name of Signer:** James Kirchner

**Title:** Treasurer